Riskpilot← Back to searchSign inGet full accessCYTOVATION ASA
ASAActiveOrg 983644600Solheimsgaten 11, 5058 BergenResearch and experimental development on natural sciences and engineering · NACE 7210Est. 20013 employees
Revenue 2024
NOK 0
EBITDA margin
—
+29% vs 2023
Equity ratio
-591.5%
Financial strength
Net profit 2024
NOK -62,9M
+23% vs 2023
| Revenue | NOK 0 | — |
| EBITDA | NOK -54,8M | +29% |
| Net profit | NOK -62,9M | +23% |
| Total assets | NOK 15,8M | -80% |
| Equity | NOK -93,3M | -207% |
| Employees | 3 | — |
Legal name
CYTOVATION ASA
Org number
983644600
Legal form
Allmennaksjeselskap
NACE code
7210 · Research and experimental development on natural sciences and engineering
Founded
6. september 2001
Share capital
NOK 9 343 855
Employees
3 (FTE)
VAT registered
No
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Daglig leder alene.
Company purpose
A) forskning, utvikling og industrialisering innen genterapi og kreftbehanling. B) kommersialisere resultater av forskning og utvikling på dette området. Drive konsulentvirksomhet eller forestå underleveranser relatert til formål som beskrevet i pkt. A og b. Selskapets formål kan også oppnås ved å erverve eiendeler i andre selskaper og delta i annen virksomhet.
Address
Solheimsgaten 11, 5058 Bergen
Email
contact@cytovation.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Staff expenses | −0 | −0 | −2 697 | −6 672 | −6 631 |
| EBITDA | −36 937 | −33 706 | −122 064 | −77 245 | −54 808 |
| Depreciation & amort. | −0 | −0 | −0 | −0 | −0 |
| EBIT | −36 937 | −33 706 | −122 064 | −77 245 | −54 808 |
| Net financials | −761 | −660 | −845 | −4 267 | −8 087 |
| Profit before tax | −37 699 | −34 365 | −122 909 | −81 512 | −62 895 |
| Tax | −0 | −0 | −0 | −0 | −0 |
| Net profit | −37 699 | −34 365 | −122 909 | −81 512 | −62 895 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 5 806 | 107 452 | 83 918 | 78 156 | 15 779 |
| Equity | −10 013 | 87 110 | 51 075 | −30 437 | −93 332 |
| Long-term debt | 0 | 10 906 | 10 906 | 91 126 | 100 239 |
| Short-term debt | 15 819 | 9 436 | 21 936 | 17 467 | 8 872 |
| Total debt | 15 819 | 20 342 | 32 842 | 108 593 | 109 111 |
EBITDA margin
-5480786200.0%
This company
15.8%
Market median
-34688520353% vs market
20202024
Equity ratio
-591.5%
This company
38.2%
Market median
-1648% vs market
20202024
Return on equity
-6289510300.0%
This company
18.4%
Market median
-34182121296% vs market
20202024
Net profit margin
-6289510300.0%
This company
8.1%
Market median
-77648275409% vs market
20202024
Asset turnover
0.00×
This company
1.12×
Market median
-100% vs market
20202024
Debt / equity
1.17×
This company
0.62×
Market median
-89% vs market
20202024
- Annual report 2024Filed via Brønnøysundsregistrene · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Brønnøysundsregistrene · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Brønnøysundsregistrene · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Brønnøysundsregistrene · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Brønnøysundsregistrene · Period 2020-01-01 – 2020-12-31
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
LP Chief Executive Officer | Chief Executive Officer | 2021 |
| Name | Role | Member since |
|---|---|---|
| Current (5) | ||
| Board of Directors | 2025 | |
| Board of Directors | 2024 | |
| Chairman | 2022 | |
| Board of Directors | 2025 | |
| Board of Directors | 2023 | |
| Former (5) | ||
| Board of Directors | 2022 – 2025 | |
| Board of Directors | 2022 – 2024 | |
| Board of Directors | 2022 – 2023 | |
| Board of Directors | 2022 – 2025 | |
| Board of Directors | 2018 – 2021 | |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Company | 34.55% | 34.55% | 2024 | |
| Company | 19.68% | 19.68% | 2024 | |
| Company | 9.92% | 9.92% | 2024 | |
| Individual | 9.9% | 9.9% | 2024 | |
| Individual | 9.86% | 9.86% | 2024 | |
| Company | 4.41% | 4.41% | 2024 | |
| Company | 2.89% | 2.89% | 2024 | |
| Company | 2.32% | 2.32% | 2024 | |
| Individual | 2.2% | 2.2% | 2024 | |
| Company | 1.76% | 1.76% | 2024 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of CYTOVATION ASA also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Lars Prestegarden | Chief Executive Officer | 0 companies |
| Hilde Hukkelberg | Board of Directors | 0 companies |
| Liv Hege Dyrnes | Board of Directors | 0 companies |
| Katherine Skye Mellis | Board of Directors | 0 companies |
| Ellen Alla Lubman | Board of Directors | 0 companies |
| Stein Christian Mohn | Chairman | 0 companies |
| Kjell Bernstrøm | Board of Directors | 0 companies |
| Martin William Dewhurst | Board of Directors | 0 companies |
| Øyvind Kongstun Arnesen | Board of Directors | 0 companies |
| Egil Hermann Sjursen | Board of Directors | 0 companies |
| Olav Hellebø | Board of Directors | 0 companies |